Search results
Results from the WOW.Com Content Network
Phenacyl bromide is the organic compound with the formula C 6 H 5 C(O)CH 2 Br. This colourless solid is a powerful lachrymator as well as a useful precursor to other organic compounds. It is prepared by bromination of acetophenone: [2] C 6 H 5 C(O)CH 3 + Br 2 → C 6 H 5 C(O)CH 2 Br + HBr. The compound was first reported in 1871. [3]
Native heparin is a polymer with a molecular weight ranging from 3 to 30 kDa, although the average molecular weight of most commercial heparin preparations is in the range of 12 to 15 kDa. [60] Heparin is a member of the glycosaminoglycan family of carbohydrates (which includes the closely related molecule heparan sulfate ) and consists of a ...
A common low molecular weight heparin drug is called enoxaparin (brand name Lovenox). Enoxaparin is listed as Pregnancy Category B, meaning animal studies have failed to show harmful effects to the fetus and therefore are safe to use in pregnant women.
Subcutaneous tinzaparin may be given at doses of 175 units of antifactor Xa activity per kg, [13] based on prepregnancy or booking weight at approximately 16 weeks, and not the current weight. [13] While unfractionated heparin is otherwise typically given in an intravenous formulation, this is inconvenient for the prolonged period of ...
The 4T score for heparin-induced thrombocytopenia [9] [10] Thrombocytopenia 2 points if the fall in platelet count is >50% of the previous value, AND the lowest count (nadir) is 20–100 × 10 9 /liter 1 point if the fall is 30–50% or the nadir is 10–19 × 10 9 /liter No points if the fall is less than 30% or the nadir is <10 × 10 9 /liter ...
Heparin is the most widely used intravenous clinical anticoagulant worldwide. [82] Heparin is a naturally occurring glycosaminoglycan. There are three major categories of heparin: unfractionated heparin (UFH), low molecular weight heparin (LMWH), and ultra-low-molecular weight heparin (ULMWH). [83]
Low-molecular-weight heparin (LMWH) is a class of anticoagulant medications. [1] They are used in the prevention of blood clots and, in the treatment of venous thromboembolism ( deep vein thrombosis and pulmonary embolism ), and the treatment of myocardial infarction .
The evidence did not identify any difference between the effects of different blood thinners on death, developing a clot, or bleeding. [2] A 2021 review found that low molecular weight heparin (LMWH) was superior to unfractionated heparin in the initial treatment of venous thromboembolism for people with cancer. [3]